BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Liu JJ, Zhou M, Yuan T, Huang ZY, Zhang ZY. Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges. World J Gastroenterol 2025; 31(15): 104901 [PMID: 40309227 DOI: 10.3748/wjg.v31.i15.104901]
URL: https://www.wjgnet.com/2218-4333/full/v31/i15/104901.htm
Number Citing Articles
1
Chelsea R. Olson, Gabriela L. Aitken, Michael W. Spinrad, Evan S. Glazer. Neoadjuvant Strategies for Patients with Resectable Biliary Tract Cancers: A ReviewCurrent Oncology 2025; 32(10): 584 doi: 10.3390/curroncol32100584
2
Michele Ghidini, Fausto Petrelli, Matteo Paccagnella, Massimiliano Salati, Francesca Bergamo, Margherita Ratti, Caterina Soldà, Barbara Galassi, Ornella Garrone, Massimo Rovatti, Arianna Zefelippo, Lucio Caccamo, Enrico Gringeri, Alessandro Zerbi, Guido Torzilli, Silvia Bozzarelli, Lorenza Rimassa, Gianluca Tomasello. Prognostic Factors and Survival Outcomes in Resected Biliary Tract Cancers: A Multicenter Retrospective AnalysisCancers 2025; 17(15): 2445 doi: 10.3390/cancers17152445
3
Jiawei Hu, Yihang Wang, Haoran Diao, Shuangda Miao, Xiaoxiao Zhang, Qi Li, Yanzhi Pan, Yun Jin, Yuanquan Yu, Jiangtao Li. Determinants and survival benefits of achieving textbook outcome for intrahepatic cholangiocarcinoma in the era of neoadjuvant therapyFrontiers in Oncology 2026; 16 doi: 10.3389/fonc.2026.1737204
4
Zengpeng Sun, Yutao Wang, Xu Chen, Lishun Yang, Ou Li, Jia Zhou, Zhiguo Tan, Chuang Peng. Surgery vs. non-surgery for advanced cholangiocarcinoma post-conversion therapy with PD-1/PD-L1 inhibitors plus TKIsFrontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1753437